Evotec (OTCMKTS:EVTCY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday, Zacks.com reports.
According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “
Separately, Deutsche Bank upgraded Evotec from a “hold” rating to a “buy” rating in a report on Wednesday, August 21st.
EVTCY stock traded up $1.55 during trading on Friday, hitting $45.20. The company had a trading volume of 100 shares, compared to its average volume of 708. The business has a 50-day moving average of $48.51 and a 200-day moving average of $50.99. Evotec has a one year low of $35.57 and a one year high of $59.50. The stock has a market cap of $3.37 billion, a PE ratio of 34.24 and a beta of 1.28. The company has a current ratio of 1.36, a quick ratio of 1.33 and a debt-to-equity ratio of 0.36.
Evotec (OTCMKTS:EVTCY) last announced its earnings results on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.26). Evotec had a net margin of 19.00% and a return on equity of 15.24%. The company had revenue of $116.02 million during the quarter. Research analysts forecast that Evotec will post 0.52 EPS for the current year.
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Further Reading: Fundamental Analysis
Get a free copy of the Zacks research report on Evotec (EVTCY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.